Laboratory Operations Innovator Chris Clendening Joins Precision for Medicine to Lead Global Specialty Labs
核心洞察
Chris Clendening, a laboratory industry veteran and technology pioneer, has been appointed General Manager of Labs Translational Sciences at Precision for Medicine (搜索).
Clendening will oversee global specialty lab operations, growth strategy, and AI-driven approaches to accelerate biomarker research in clinical trials.
He previously served as SVP of Biotechnology Operations at Clario (搜索) and spent over a decade at PPD Central Labs (搜索), where he received the Center Watch Award for Innovation.
Precision for Medicine (搜索), a global leader in biomarker-driven clinical research and development, announced today that laboratory industry veteran and technology pioneer Chris Clendening has joined the company as General Manager, Labs Translational Sciences. Reporting to Sofia Baig, President of Precision for Medicine, Clendening will oversee the company's global specialty labs business, including worldwide operational delivery, growth strategy, and the enrichment of AI-driven approaches that accelerate biomarker research.
The appointment, effective July 14, 2026, positions Clendening at the helm of Precision's specialty laboratory services at a time when the clinical research industry is undergoing rapid transformation driven by artificial intelligence and the expanding role of biomarkers in drug development.
A Track Record of Laboratory Innovation
Clendening brings extensive experience in global laboratory strategy, operations, and commercial growth across complex clinical trial environments. He most recently served as Senior Vice President of Biotechnology Operations and Product Development at Clario (搜索). Prior to that, he spent more than a decade in executive leadership roles at PPD Central Labs (搜索), where he was the primary driver and operational architect behind the development of what the company describes as an evolutionary central laboratory platform. For his contributions, Clendening received the prestigious Center Watch Award for Innovation.
"Chris's arrival is a powerful validation of Precision's market position," said Baig. "We were built to serve innovators who are actively challenging the status quo, and Chris is a proven strategic leader in a field that is rapidly evolving due to AI drug development and the increasing use of biomarkers. He has spent his career rethinking laboratory operations to improve speed, efficiency and clinical outcomes."
AI and the Next Generation of Specialty Lab Services
Clendening's mandate includes leveraging Precision's organizational agility to build smarter, more efficient laboratory solutions. He emphasized the transformative potential of artificial intelligence in the clinical laboratory space.
"I am deeply inspired by Precision's open, collaborative culture and the leadership team's clear commitment to continued growth," said Clendening. "Our industry is evolving rapidly, and the potential of AI to bend the time-cost curve in the lab and in clinical trials is immense. Precision is uniquely positioned to deliver the next generation of specialty laboratory services."
He further noted that legacy organizations often face structural difficulties pivoting away from traditional operating models, whereas Precision has the flexibility to move quickly and build more efficient solutions. In his new role, Clendening will focus on global operational delivery and driving highly integrated, novel scientific solutions for Precision clients worldwide.
Background and Leadership Philosophy
Clendening holds a Bachelor of Science in biology and chemistry from Muskingum University. He resides in Cincinnati, Ohio, with his wife and five children. He attributes his disciplined, execution-focused leadership style to his upbringing on a family dairy farm, where he learned the value of daily accountability, consistency, and follow-through.
About Precision for Medicine (搜索)
Precision for Medicine (搜索) is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. The organization applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise, and advanced data intelligence. Precision for Medicine is part of Precision Medicine Group, which employs over 3,500 people across more than 50 locations globally in the Americas, Europe, and Asia-Pacific.